Fate Therapeutics’ FT819 shows responses in three lupus patients without conditioning chemotherapy
FATE•Fate Therapeutics reported responses in all three extrarenal lupus patients treated with FT819 without conditioning chemotherapy; two achieved remission and one reached low disease activity. Safety findings across 36 patients showed no dose-limiting toxicities.
1. Lupus trial results
Fate Therapeutics is presenting updated Phase 1 FT819 results at ACR Convergence 2026. All three patients with extrarenal lupus treated without conditioning chemotherapy responded, with two achieving remission and one reaching low disease activity. Safety findings across 36 patients showed no dose-limiting toxicities.
2. Repeat dosing
The first patient to receive two FT819 doses achieved sustained low disease activity, supporting further evaluation of repeat dosing. Preclinical FT839 results presented at the meeting support broader immune-cell targeting in rheumatoid arthritis, and its Phase 1/2 COMPLETE trial is enrolling.
